You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 164 No. 11, June 14, 2004 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Investigation
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (14)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Adverse Effects
 •Alert me on articles by topic

Reported Adverse Event Cases of Methemoglobinemia Associated With Benzocaine Products

Thomas J. Moore; Christopher S. Walsh, PharmD; Michael R. Cohen, RPh, MS, DSc

Arch Intern Med. 2004;164:1192-1196.

Background  Methemoglobinemia (MHb) is characterized by abnormal levels of oxidized hemoglobin that cannot bind and transport oxygen. When induced by benzocaine anesthetic spray and other chemicals, it can result in cyanosis and life-threatening complications.

Methods  From 818 439 adverse event reports received by the US Food and Drug Administration from November 1997 through March 2002, we extracted every report for use of a benzocaine product. We classified each case by product type (eg, spray, gel, or solution), by whether MHb was involved, and by the dose given.

Results  Among 198 reported adverse events of all types associated with benzocaine, 132 cases (66.7%) involved definite or probable MHb. The MHb cases included 107 serious adverse events (81.1%) and 2 deaths (1.5%). In 123 cases (93.2%), the product was a spray; in 2 cases (1.5%), a benzocaine-containing lozenge; and 1 case, a gel. In the 69 cases that specified a dose, 37 (53.6%) indicated that a single spray was applied (approximately the recommended amount).

Conclusions  Health professionals involved in endoscopy, intubation, bronchoscopy, or similar invasive procedures using benzocaine-containing sprays should know that (1) administration may cause MHb with potentially serious consequences, (2) identifying the reaction to benzocaine usually requires cooximetry (although it can be implied by symptoms), and (3) treatment involves immediate intravenous administration of 1 to 2 mg/kg of methylene blue.


From the Institute for Safe Medication Practices, Huntingdon Valley, Pa (Mr Moore and Drs Walsh and Cohen), and the Center for Health Services Research and Policy, The George Washington University School of Public Health and Health Services, Washington, DC (Mr Moore). The authors have no relevant financial interest in this article.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Toxicology in the Critical Care Unit
Alapat and Zimmerman
Chest 2008;133:1006-1013.
ABSTRACT | FULL TEXT  

Benzocaine: Not Dangerous Enough?
Calello et al.
Pediatrics 2005;115:1452-1452.
FULL TEXT  

Methemoglobinemia Secondary to Topical Benzocaine Use in a Lung Transplant Patient
LeClaire et al.
The Annals of Pharmacotherapy 2005;39:373-376.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2004 American Medical Association. All Rights Reserved.